
Clinical TrialNov 17, 2026, 09:08 AM
MetaVia Completes Phase 1 Trial for DA-1726; Shows 68.1% Liver Fat Reduction
AI Summary
MetaVia Inc. announced the completion of the last patient visit for its Phase 1 clinical trial evaluating DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The company extended the treatment period from 16 to 24 weeks based on encouraging preliminary safety and tolerability observations. Interim data from Part 3B showed a statistically significant 68.1% placebo-adjusted reduction in liver fat, 13.5% placebo-adjusted weight loss, and improvements in glycemic control. Full data from Parts 3A and 3B are expected in Q1 2027, with a Phase 2 study planned for the second half of 2027.
Key Highlights
- Last patient completed final study visit for Phase 1 clinical trial of DA-1726.
- Treatment period extended to 24 weeks based on positive safety and tolerability.
- Part 3B interim data showed 68.1% placebo-adjusted reduction in liver fat.
- Part 3B interim data showed 13.5% placebo-adjusted weight loss.
- Full data from Parts 3A and 3B expected in Q1 2027.
- Phase 2 study in MetALD and ALD planned for second half of 2027.
Price Impact
More from MTVA